Bilobalide

Bilobalide
Clinical data
Routes of; administration	By mouth
Legal status
Legal status	In general: legal;
Identifiers
	IUPAC name (5aR-(3aS,5aα,8b,8aS,9a,10aα))-9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-4H,5aH,9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione;
CAS Number	33570-04-6 ;
PubChem CID	73581;
IUPHAR/BPS	2366;
ChemSpider	21106418 ;
UNII	M81D2O8H7U;
ChEBI	CHEBI:3103;
ChEMBL	ChEMBL133266 ;
CompTox Dashboard (EPA)	DTXSID10873207 ;
ECHA InfoCard	100.125.716
Chemical and physical data
Formula	C15H18O8
Molar mass	326.301 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@]1(C[C@H]2[C@@]3([C@]14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O;
	InChI InChI=1S/C15H18O8/c1-12(2,3)14(20)4-6-13(5-7(16)21-6)10(19)23-11-15(13,14)8(17)9(18)22-11/h6,8,11,17,20H,4-5H2,1-3H3/t6-,8-,11-,13-,14+,15?/m0/s1 ; Key:MOLPUWBMSBJXER-ISSLQHLCSA-N ;
	(what is this?) (verify)

Bilobalide is a biologically active terpenic trilactone present in Ginkgo biloba.^[1]

Chemistry

Bilobalide is a main constituent of the terpenoids found in Ginkgo leaves. It also exists in minor amounts in the roots. It is a sesquiterpenoid, i.e. it has a 15-carbon skeleton. Its exact synthesis pathway from farnesyl pyrophosphate is still unknown.

Biosynthesis

Bilobalide and ginkgolide have similar biosynthetic pathways. Bilobalide is formed by partially degraded ginkgolide. Bilobalide is derived from geranylgeranyl pyrophosphate (GGPP), which is formed by addition of farnesyl pyrophosphate (FPP) to an isopentenyl pyrophosphate (IPP) unit to form a C₁₅ sesquiterpene. Such formation went through the mevalonate pathway (MVA) and methylerythritol phosphate MEP pathway. In order to generate bilobalide, C₂₀ ginkgolide 13 must form first. To transform from GGPP to abietenyl cation 5, a single bifunctional enzyme abietadiene synthase E1 is required. However, due to the complexity of ginkgolide structures for rearrangement, ring cleavage, and formation of lactone rings, diterpene 8 is used to explain instead. Levopimaradiene 6 and abietatriene 7 are precursors for ginkgolide and bilobalide formation. The unusual tert-butyl substituent is formed from A ring cleavage in 9. Bilobalide 13 then formed in loss of carbons through degradation from ginkgolide 12, and lactones are formed from residual carboxyl and alcohol functions. The end product of bilobalide contains sesquiterpenes and three lactones units.^[2]

Pharmacology

Bilobalide is important for producing several of the effects of Ginkgo biloba extracts, and it has neuroprotective effects,^[3]^[4] as well as inducing the liver enzymes CYP3A1 and 1A2,^[5] which may be partially responsible for interactions between ginkgo and other herbal medicines or pharmaceutical drugs. Bilobalide has recently been found to be a negative allosteric modulator at the GABA_A and GABA_A-rho receptors.^[6]^[7] Of GABA_A, it may possibly be selective for the subunits predominantly implicated in cognitive and memory functioning such as α1^{[citation needed]}.

References

^ van Beek TA, Montoro P (2009). "Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals". Journal of Chromatography A. 1216 (11): 2002–32. doi:10.1016/j.chroma.2009.01.013. PMID 19195661.
^ Dewick, P. M. Medicinal Natural Products: Products:A Biosynthetic Approach. Third Edition ed.; Wiley&Sons: West Sussex, England, 2009; p 230-232.
^ Defeudis FV (2002). "Bilobalide and neuroprotection". Pharmacological Research. 46 (6): 565–8. doi:10.1016/S1043-6618(02)00233-5. PMID 12457632.
^ Kiewert C, Kumar V, Hildmann O, Hartmann J, Hillert M, Klein J (2008). "Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide". Brain Research. 1201: 143–50. doi:10.1016/j.brainres.2008.01.052. PMID 18325484. S2CID 5191088.
^ Deng Y, Bi HC, Zhao LZ, He F, Liu YQ, Yu JJ, Ou ZM, Ding L, Chen X, Huang ZY, Huang M, Zhou SF (2008). "Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats". Xenobiotica. 38 (5): 465–81. doi:10.1080/00498250701883233. PMID 18421621. S2CID 84019088.
^ http://sydney.edu.au/medicine/pharmacology/adrien-albert/images/pdfs/RefsPDFs/376.pdf ^{[bare URL PDF]}
^ "Archived copy" (PDF). sydney.edu.au. Archived from the original (PDF) on 9 November 2020. Retrieved 12 January 2022.{{cite web}}: CS1 maint: archived copy as title (link)

External links

Media related to Bilobalide at Wikimedia Commons

[pmid19195661-1] van Beek TA, Montoro P (2009). "Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals". Journal of Chromatography A. 1216 (11): 2002–32. doi:10.1016/j.chroma.2009.01.013. PMID 19195661.

[2] Dewick, P. M. Medicinal Natural Products: Products:A Biosynthetic Approach. Third Edition ed.; Wiley&Sons: West Sussex, England, 2009; p 230-232.

[pmid12457632-3] Defeudis FV (2002). "Bilobalide and neuroprotection". Pharmacological Research. 46 (6): 565–8. doi:10.1016/S1043-6618(02)00233-5. PMID 12457632.

[pmid18325484-4] Kiewert C, Kumar V, Hildmann O, Hartmann J, Hillert M, Klein J (2008). "Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide". Brain Research. 1201: 143–50. doi:10.1016/j.brainres.2008.01.052. PMID 18325484. S2CID 5191088.

[pmid18421621-5] Deng Y, Bi HC, Zhao LZ, He F, Liu YQ, Yu JJ, Ou ZM, Ding L, Chen X, Huang ZY, Huang M, Zhou SF (2008). "Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats". Xenobiotica. 38 (5): 465–81. doi:10.1080/00498250701883233. PMID 18421621. S2CID 84019088.

[6] ttp://sydney.edu.au/medicine/pharmacology/adrien-albert/images/pdfs/RefsPDFs/376.pdf ^{[bare URL PDF]}

[7] "Archived copy" (PDF). sydney.edu.au. Archived from the original (PDF) on 9 November 2020. Retrieved 12 January 2022.{{cite web}}: CS1 maint: archived copy as title (link)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Chemistry

Biosynthesis

Pharmacology

See also

References

External links